Clinical Advances in
Glycemic control remains the cornerstone of management of type 2 diabetes (T2D) as it plays a vital role in preventing or delaying the onset and progression of complications. Individualizing therapeutic goals and using modern antihyperglycemic agents when appropriate is crucial to safe and effective management of T2D. These educational activities aim to increase awareness of cardiovascular outcomes data and provide practical strategies to help patients achieve T2D goals using combination therapy.
Supported by
AstraZeneca
Steering Committee Chair
Professor, Keck School of Medicine of the University of Southern California; Director, USC Clinical Diabetes Programs, University of Southern California, Los Angeles, California
The Frist Clinic, Nashville, Tennessee
Director, Ochsner Diabetes Clinical Research Unit, Frank Riddick Diabetes Institute, Department of Endocrinology, Ochsner Medical Center, New Orleans, Louisiana
Clinical Professor, University of California at San Diego; Medical Director, Scripps Whittier Diabetes Institute, La Jolla, California
Clinical Professor of Medicine, University of Texas Southwestern Medical Center; Director, Dallas Diabetes and Endocrine Center at Medical City, Dallas, Texas
Clinical Professor of Medicine, University of Washington, Spokane, Washington